Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai President Looking To Acquire Generics Maker

This article was originally published in PharmAsia News

Executive Summary

Eisai is looking for a generics drug maker to acquire in an effort to build its position in the markets developing in emerging countries, President Harua Naito says. Naito said in an interview his company considers the business of generic drugs as different from that of making innovative drugs, so it would be difficult for Eisai to make the switch on its own. The company's newly opened European Knowledge Center in London affords Eisai the capacity to carry out all aspects of the drug business in a third location, in addition to current operations in Japan and the United States. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts